What is Interpace Biosciences, Inc. worth?
With the base-case assumptions below, a discounted cash flow model on Interpace Biosciences, Inc.'s reported free cash flow gives $3.40 per share. The share price was $6.41 on September 25, 2026, 88% above that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | -1.5% | 10.0% | $2.18 | -66% |
| Base | 3.5% | 9.0% | $3.40 | -47% |
| Bull | 8.5% | 8.0% | $5.85 | -9% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $4.29 | $4.56 | $4.89 | $5.30 | $5.83 |
| 8.0% | $3.63 | $3.81 | $4.01 | $4.26 | $4.56 |
| 9.0% | $3.15 | $3.27 | $3.40 | $3.57 | $3.76 |
| 10.0% | $2.78 | $2.86 | $2.96 | $3.07 | $3.20 |
| 11.0% | $2.49 | $2.55 | $2.62 | $2.70 | $2.78 |
Where the presets come from
Base: years 1 to 5 grow at Interpace Biosciences, Inc.'s revenue growth rate over the last 5 fiscal years (3.6% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions